Inhibition of telomerase activity by HDV ribozyme in cancers
2011
Inhibition of Telomerase Activity by HDV Ribozyme in Cancers
publication
Evidence: moderate
Author Information
Author(s): Lu Yingying, Gu Junchao, Jin Dachuan, Gao Yanjing, Yuan Mengbiao
Primary Institution: Beijing Friendship Hospital affiliated to Capital Medical University
Hypothesis
Can HDV ribozyme effectively inhibit telomerase activity in cancer cells?
Conclusion
The HDV ribozyme is an effective strategy for gene therapy, significantly reducing telomerase activity in cancer cells.
Supporting Evidence
- The HDV ribozyme showed a maximum cleavage ratio of about 70.4% against telomerase RNA.
- Transfection of HDV ribozyme into cancer cells led to a significant drop in telomerase activity to 10% of the original level.
- Ribozyme-transfected cells exhibited increased apoptosis and cell cycle arrest.
Takeaway
This study shows that a special RNA molecule can stop cancer cells from growing by cutting their telomerase, which helps them live longer.
Methodology
The study involved designing and synthesizing an HDV ribozyme, transfecting it into cancer cells, and measuring its effects on telomerase activity and cell growth.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website